Ceregene to Present at JPMorgan 26th Annual Healthcare Conference

Jan 07, 2008, 00:00 ET from Ceregene, Inc.

    SAN DIEGO, Jan. 7 /PRNewswire-FirstCall/ -- Ceregene, Inc. today
 announced that Jeffrey M. Ostrove, Ph.D., president and chief executive
 officer, will present at the JPMorgan 26th Annual Healthcare Conference in
 San Francisco, CA on Thursday, January 10th at 11:30 a.m. PST.
     "We look forward to participating in this pre-eminent healthcare
 conference and providing a Ceregene update to the investment community,"
 stated Dr. Ostrove. "2007 was a positive year for us during which time we
 raised our Series C financing, signed a corporate partnership deal with
 Genzyme and announced encouraging data from both our clinical-stage
 Parkinson's disease and Alzheimer's disease programs. We expect to report
 Phase 2 data from our controlled CERE-120 Parkinson's disease study late
 this year, which could lead to a Phase 3 clinical study in 2009. We also
 look forward to the initiation of a larger, controlled Phase 2 trial of
 CERE-110 in Alzheimer's disease later this year."
     About Ceregene
     Ceregene, Inc. is a San Diego-based biotechnology company focused on
 the delivery of nervous system growth factors for the treatment of
 neurodegenerative disorders using gene delivery. Ceregene's clinical
 programs include CERE-110, an AAV2 based vector expressing nerve growth
 factor that is currently in Phase 1/2 studies for the treatment of
 Alzheimer's disease, and CERE-120 (AAV2-Neurturin) which recently completed
 enrollment of a controlled Phase 2 study for Parkinson's disease. CERE-130
 and CERE-140 are in preclinical development for ALS (Lou Gehrig's disease)
 and ocular disorders, respectively. Ceregene was launched in January 2001
 and is a former subsidiary of Cell Genesys, Inc. (Nasdaq:   CEGE). The
 company's investors include Alta Partners, MPM Capital, Investor Growth
 Capital and Cell Genesys as well as Hamilton BioVentures and California
 Technology Partners.

SOURCE Ceregene, Inc.